Polarean Imaging PLC Scientific presentations on hyperpolarized Xenon
30 July 2020 - 4:00PM
RNS Non-Regulatory
TIDMPOLX
Polarean Imaging PLC
30 July 2020
Polarean Imaging plc
("Polarean" or the "Company")
Scientific presentations on hyperpolarized (129) Xenon at
upcoming medical meetings
- Polarean's investigational drug/device lung diagnostic to be prominently featured
- Multiple hyperpolarized Xenon MRI presentations to be
highlighted at two major upcoming scientific conferences
Polarean Imaging plc (AIM: POLX), the medical -- imaging
technology company, with a proprietary drug -- device combination
diagnostic for the magnetic resonance imaging (MRI) market,
announces a number of presentations highlighting the use of
hyperpolarized Xenon 129 ("(129) Xe") will be made by leading
academic researchers at the upcoming American Thoracic Society
("ATS") virtual conference and the International Society for
Magnetic Resonance in Medicine ("ISMRM") virtual conference. The
ATS and ISMRM conferences are taking place between 5-10 August 2020
and 8-14 August 2020, respectively.
Over 40 abstracts related to the use of hyperpolarized (129) Xe
were accepted for presentation at ATS 2020. The abstracts listed
below are among those that will be presented as posters on
Wednesday, 5 August 2020:
ATS 2020 Abstract Title and Lead Author Poster Number Session Number
Coleman EM et al. Hyperpolarized (129) 523 D28
Xe Identifies Ventilation Responders
to Glycopyrrolate/Formoterol Furmarate
in Chronic Obstructive Lung Disease
-------------- ---------------
Bier EA et al. Monitoring Response 593 B56
to Inhaled Prostacyclin Therapy with
(129) Xenon MR Imaging and Spectroscopy
in Patients with Pulmonary Hypertension
-------------- ---------------
Neidbalski PJ et al. Hyperpolarized 622 A68
(129) Xe MRI of Regional Capillary-Level
Cardio-Pulmonary Dynamics Predict Outcomes
in IPF Patients
-------------- ---------------
Bier EA et al. Noninvasive Diagnosis 633 B58
of Pulmonary Hypertension with Hyperpolarized
(129) Xe Magnetic Resonance Imaging
and Spectroscopy
-------------- ---------------
Mummy D et al. Hyperpolarized Xe-129 705 D110
MRI Measures of Gas Exchange in Non-specific
Interstitial Pneumonia
-------------- ---------------
Wang Z et al. Spatial Correlation of 706 D110
(129) Xenon Gas Exchange MRI with (99m)
Tc Perfusion Scintigraphy
-------------- ---------------
Wang Z et al. Using (129) Xenon MR 707 D110
Gas Exchange MRI to Measure the Membrane
and Capillary Components of DL(CO)
and K(CO)
-------------- ---------------
Mummy D et al. Hyperpolarized (129) 713 D110
Xe MRI is sensitive to therapy response
in idiopathic pulmonary fibrosis
-------------- ---------------
Shim YM et al. Positive Results from 1027 B39
Two Randomized Phase III Trials Assessing
Hyperpolarized 129Xenon
Gas MRI as a Measure of Regional Lung
Function as Compared to Imaging with
133Xenon Scintigraphy
-------------- ---------------
Presentations of the following accepted abstracts will be
delivered at ISMRM on the following days and times:
ISMRM 2020 Abstract Title and Lead Program Session Name Date
Author Number
Bier EA et al. Noninvasive Diagnosis 2283 Hyperpolarized 8-14 August
of Pulmonary Hypertension with Hyperpolarized Gas/Lung
(129) Xe Magnetic MRI
Resonance Imaging and Spectroscopy
-------- --------------- ------------
Mummy D et al. Hyperpolarized (129) 2291 Thoracic 8-14 August
Xe MRI Measures of Gas Exchange in & Breast
Non-specific Interstitial Pneumonia MRI
-------- --------------- ------------
Niedbalski PJ et al. Imaging Regional 0432 Thoracic 11 August
Capillary Cardio-Pulmonary Blood Flow MRI
Dynamics using Hyperpolarized (129)
Xe MRI and Keyhole Reconstruction
-------- --------------- ------------
Rankine L et al. Quantitative dose-dependent 0431 Thoracic 11 August
changes in regional lung function MRI
after radiation therapy detected using
xenon-129 gas exchange MRI
-------- --------------- ------------
Lu J et al. Bias field correction 0451 Pulmonary 11 August
in hyperpolarized (129) Xe ventilation Power
imaging
-------- --------------- ------------
Wang Z et al. A model for interpreting 0443 Pulmonary 11 August
hyperpolarized (129) Xe exchange MRI Power
-------- --------------- ------------
Additionally, Talissa Altes, MD, Professor and Chair of
Radiology at the University of Missouri will be delivering a
presentation on Xenon lung magnetic resonance imaging (MRI) during
the Lung/Thoracic MRI Session W-02 during ISMRM. Session W-02 takes
place on Tuesday, 11 August from 1:45 to 2:30 p.m. ET.
Richard Hullihen, Chief Executive Officer of Polarean commented:
"We are pleased to see (129) Xenon in MRI highlighted at these key
scientific meetings. It is a testament to the growing interest in
exploring hyperpolarized (129) Xenon as a way of advancing the use
of MRI in a non-invasive, non-ionizing functional imaging platform
to assist with the early diagnosis of respiratory diseases. As well
as this, it can be used to monitor progression and therapeutic
response in the patient. Many of the projects being presented at
these two leading conferences have made use of Polarean's products
to conduct research, highlighting the growing academic acceptance
of the Company's technology. We hope that the inclusion of so many
sessions on (129) Xenon will continue to showcase Polarean's
important work in the field as we continue to progress discussions
with the regulator regarding the clinical use of our drug-device
system."
Contacts:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Via Walbrook PR
Officer
Jonathan Allis, Chairman
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44 (0)7876
741 001
About Polarean ( www.polarean.com )
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue-generating, medical drug-device
combination companies operating in the high-resolution medical
imaging market.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specializes in the use of hyperpolarized Xenon gas ((129) Xe) as an
imaging agent to visualize ventilation.(129) Xe gas is currently
being studied for visualization of gas exchange regionally in the
smallest airways of the lungs, the tissue barrier between the lung,
and the bloodstream and in the pulmonary vasculature. Xenon gas
exhibits solubility and signal properties that enable it to be
imaged within other tissues and organs.
The Group also develops high performance MRI radiofrequency (RF)
coils which are a required component for imaging (129) Xe in the
MRI system. The development of these coils by the Group facilitates
emerging applications.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEAKXNALEEEFA
(END) Dow Jones Newswires
July 30, 2020 02:00 ET (06:00 GMT)
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Apr 2024 to May 2024
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From May 2023 to May 2024